CCBIO Seminar – Linda Lindström
Welcome to the CCBIO seminar series in the spring term 2023. Open to all in auditorium 4, BBB. Speaker is Linda Lindström. No registration necessary. Join us also for the informal pizza get-together in the hall following the talk!
Speaker: Linda Lindström, Associate Professor in Cancer Epidemiology and group leader at the Department of Oncology and Pathology, Karolinska Institute, Sweden
Title: Breast cancer inter and intra-patient heterogeneity and long-term risk to develop distant metastatic disease
Host: Lars A. Akslen
Where: Auditorium 4, BB-building
When: April 27, 2023 at 14.30-15.30
No registration necessary. Join us also for the informal pizza get-together in the hall following the talk!
Most breast cancer patients are diagnosed with hormone-dependent (estrogen receptor-positive, ER+) breast cancer and anti-hormonal (endocrine) treatment is standard of care. Unlike most other cancers, the risk of fatal disease remains stable beyond 5 to 10 years after diagnosis, and half or more of all breast cancer metastases will be diagnosed long-term after this initial follow-up. The tumor biological factors underlying long-term risk are poorly understood, but clinically important in particular for younger premenopausal patients with a long post cancer life expectancy but also decades of fear from disease recurrence. Young women with breast cancer also have a worse prognosis as compared to older postmenopausal women, and menopausal status itself has been suggested to be an independent risk factor related to the hormonal milieu. In my research group, our focus is on long-term risk and how risk and endocrine treatment benefit is influenced by menopausal status and tumor biology including standard tumor markers, intra-tumor heterogeneity, and tumor microenvironment.
Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. J Clin Oncol. 2022. PMID: 35862873.
Yu N, Iftimi A, Yau C, Tobin NP, van ’t Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with Luminal A or Luminal B breast cancer. JAMA Oncol. 2019. PMID: 31393518.
Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van’t Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group. Intra-tumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast Cancer. J Natl of Cancer Inst, (JNCI). 2018. PMID: 29361175.